Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 4/20 | 0.58 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 7/20 | 0.36 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.35 |
| ▸ | IDH1 | O75874 | 2/20 | 0.35 |
| ▸ | IGF1R | P08069 | 1/20 | 0.35 |
| ▸ | IDH2 | P48735 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15768991 | 0.80 | HDAC4 (0.68) | HDAC4SLC6A7SYKTAS2R14IGF1R | |
| SCHEMBL12499633 | 0.80 | HDAC4 (0.68) | HDAC4SLC6A7SYKTAS2R14IGF1R | |
| SCHEMBL15606946 | 0.77 | HDAC4 (0.76) | HDAC4SLC6A7SYKTAS2R14IDH1 | |
| SCHEMBL15768990 | 0.74 | HDAC4 (0.74) | HDAC4SLC6A7MAPTSYK | |
| SCHEMBL15606850 | 0.73 | HDAC4 (1.00) | HDAC4SLC6A7SYKTAS2R14 | |
| SCHEMBL15606874 | 0.73 | HDAC4 (1.00) | HDAC4SLC6A7SYKTAS2R14 | |
| SCHEMBL15547318 | 0.73 | HDAC4 (0.55) | HDAC4 | |
| SCHEMBL2138274 | 0.71 | HDAC4 (0.56) | HDAC4SLC6A7MAPTKMT2ASYK | |
| SCHEMBL23683043 | 0.71 | HDAC4 (0.68) | HDAC4SLC6A7SYKIDH1IDH2 | |
| SCHEMBL4172326 | 0.71 | SYK (0.56) | HDAC4SLC6A7SYKTAS2R14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9855267-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170042892-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2017-02-16 | — | — | US | disclosed |
| US-9505736-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150203468-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2015-07-23 | — | — | US | disclosed |
| EP-2871955-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI Foundation, Inc. (US) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014014900-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. (US) | 2014-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170042892-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | HDAC1, HDAC7, HDAC5 | HDAC4 10/4885SLC6A7 2607/4885SMN1; SMN2 3271/4885 |
| US-20150203468-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | HDAC1, HDAC7, HDAC5 | HDAC4 10/4885SLC6A7 2607/4885SMN1; SMN2 3271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.